{"entity":{"id":"michael-bloomberg","kind":"person","name":"Michael Bloomberg","aka":[],"tldr":"In 2016 his $50 million, matched by Sidney Kimmel and others to $125 million, launched a Johns Hopkins institute that put more than a hundred scientists and clinicians to work on cancer immunotherapy.","summary":"Michael Bloomberg's gifts to Johns Hopkins, his alma mater, exceeded $1.2 billion by 2016 according to the university. In March 2016 he gave $50 million, matched by $50 million from Sidney Kimmel and $25 million from a dozen other donors, to found the Bloomberg~Kimmel Institute for Cancer Immunotherapy, uniting more than 100 Hopkins scientists and clinicians on the biology of immune checkpoints, T-cell engineering and the tumour microenvironment, in coordination with the national Cancer Moonshot then led by Vice President Biden. The institute built on Hopkins work that had helped establish PD-1 blockade and the use of mismatch-repair deficiency as a marker for who responds to it. His broader public health philanthropy, on tobacco control in particular, bears on cancer prevention worldwide.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Michael_Bloomberg","links":[{"label":"Johns Hopkins Hub: cancer immunotherapy institute launch (2016)","url":"https://hub.jhu.edu/2016/03/29/cancer-immunotherapy-center-bloomberg-kimmel/"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":["immunotherapy","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":["drew-pardoll","suzanne-topalian","sidney-kimmel"],"bottlenecks":["b-funding-allocation","b-immunotherapy-response","b-prevention-adoption"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Johns Hopkins' largest benefactor; co-founder of the Bloomberg~Kimmel Institute for Cancer Immunotherapy","specialisms":["Cancer immunotherapy","Institute building","Public health philanthropy"],"profiles":[],"papers":[]},"route":"/people/michael-bloomberg/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"institution":[{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/"}],"person":[{"id":"drew-pardoll","kind":"person","name":"Drew M. Pardoll","route":"/people/drew-pardoll/"},{"id":"sidney-kimmel","kind":"person","name":"Sidney Kimmel","route":"/people/sidney-kimmel/"},{"id":"suzanne-topalian","kind":"person","name":"Suzanne L. Topalian","route":"/people/suzanne-topalian/"}],"bottleneck":[{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/"},{"id":"b-immunotherapy-response","kind":"bottleneck","name":"No one can predict who responds to immunotherapy","route":"/bottlenecks/b-immunotherapy-response/"},{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/"}]}}